Trial Profile
Study of Administration of Intravenous Naglazyme Following Allogeneic Transplantation for Maroteaux-Lamy Syndrome
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 28 Dec 2020
Price :
$35
*
At a glance
- Drugs Galsulfase (Primary)
- Indications Mucopolysaccharidosis VI
- Focus Therapeutic Use
- 22 Dec 2020 Status changed from active, no longer recruiting to discontinued.
- 16 Sep 2019 Planned End Date changed from 1 Sep 2019 to 1 Sep 2020.
- 16 Sep 2019 Planned primary completion date changed from 1 Sep 2019 to 1 Sep 2020.